Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 19;9(11):e20904.
doi: 10.2196/20904.

Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial

Edgard Diniba Dabira  1 , Harouna M Soumare  1 , Steven W Lindsay  2 , Bakary Conteh  1 , Fatima Ceesay  1 , John Bradley  3 , Christian Kositz  3 , Henk Broekhuizen  4 , Balla Kandeh  5 , Alexandra E Fehr  6   7 , Claudia Nieto-Sanchez  6 , Joan Muela Ribera  8 , Koen Peeters Grietens  6 , Menno Roderick Smit  9   10 , Chris Drakeley  3 , Teun Bousema  4 , Jane Achan  1 , Umberto D'Alessandro  1
Affiliations

Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial

Edgard Diniba Dabira et al. JMIR Res Protoc. .

Abstract

Background: With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission.

Objective: The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions.

Methods: The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of ~2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans.

Results: The MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked.

Conclusions: This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission.

Trial registration: ClinicalTrials.gov NCT03576313; https://clinicaltrials.gov/ct2/show/NCT03576313.

International registered report identifier (irrid): DERR1-10.2196/20904.

Keywords: The Gambia; cluster randomized trial; dihydroartemisinin-piperaquine; ivermectin; malaria; mass drug administration.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

References

    1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briët O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015 Oct 08;526(7572):207–211. doi: 10.1038/nature15535. http://europepmc.org/abstract/MED/26375008 - DOI - PMC - PubMed
    1. World Malaria Report 2019. World Health Organization. [2020-05-31]. https://www.who.int/publications-detail/world-malaria-report-2019.
    1. Ceesay S, Casals-Pascual C, Erskine J, Anya S, Duah N, Fulford A, Sesay SS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA, Whittle HC, Greenwood BM, Conway DJ. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. The Lancet. 2008 Nov;372(9649):1545–1554. doi: 10.1016/s0140-6736(08)61654-2. - DOI - PMC - PubMed
    1. Ceesay SJ, Casals-Pascual C, Nwakanma DC, Walther M, Gomez-Escobar N, Fulford AJC, Takem EN, Nogaro S, Bojang KA, Corrah T, Jaye MC, Taal MA, Sonko AAJ, Conway DJ. Continued decline of malaria in The Gambia with implications for elimination. PLoS One. 2010 Aug 18;5(8):e12242. doi: 10.1371/journal.pone.0012242. https://dx.plos.org/10.1371/journal.pone.0012242 - DOI - DOI - PMC - PubMed
    1. Mwesigwa J, Okebe J, Affara M, Di Tanna GL, Nwakanma D, Janha O, Opondo K, Grietens KP, Achan J, D'Alessandro U. On-going malaria transmission in The Gambia despite high coverage of control interventions: a nationwide cross-sectional survey. Malar J. 2015 Aug 14;14(1):314. doi: 10.1186/s12936-015-0829-6. https://malariajournal.biomedcentral.com/articles/10.1186/s12936-015-0829-6 - DOI - DOI - PMC - PubMed

Associated data